Relmada Therapeutics, Inc. (NASDAQ:RLMD – Get Free Report) CFO Maged Shenouda acquired 6,875 shares of Relmada Therapeutics stock in a transaction dated Wednesday, January 31st. The stock was bought at an average price of $4.06 per share, with a total value of $27,912.50. Following the completion of the purchase, the chief financial officer now directly […]
Relmada Therapeutics, Inc. (NASDAQ:RLMD – Get Free Report) insider Chuck Ence bought 14,500 shares of the stock in a transaction dated Tuesday, January 30th. The stock was purchased at an average cost of $3.87 per share, for a total transaction of $56,115.00. Following the acquisition, the insider now owns 25,300 shares of the company’s stock, […]
Relmada Therapeutics, Inc. (NASDAQ:RLMD – Get Free Report) CEO Sergio Traversa bought 31,541 shares of the firm’s stock in a transaction that occurred on Monday, January 29th. The stock was purchased at an average price of $3.71 per share, with a total value of $117,017.11. Following the completion of the purchase, the chief executive officer […]
Relmada Therapeutics, Inc. (NASDAQ:RLMD – Get Free Report) CFO Maged Shenouda bought 6,875 shares of the company’s stock in a transaction dated Wednesday, January 31st. The shares were purchased at an average price of $4.06 per share, with a total value of $27,912.50. Following the completion of the acquisition, the chief financial officer now owns […]